Key Highlights
-
U.S. Levodopa prices inched up by +*.*** in August ****, reflecting cautious procurement.
-
Demand remains steady and non-seasonal, tied to Parkinson’s disease treatment.
-
Upcoming Golden Week holiday in China may disrupt exports and elevate freight costs.
-
Buyers may slightly increase procurement in September to safeguard against delays.
-
U.S. inflation continues to exert cost pressure across pharmaceutical supply chains.
In August ****, US Levodopa pricing was generally flat, with a gentle gain of +*.***. The gentle re-pricing indicates the strength of demand for the medication, supported by steady medical demand as opposed to seasonal conditions. Purchasers and sellers continued with guarded buying habits, with no bulk stockpiling as supply conditions were still firm.
Through to September, the market will probably see another soft upward revision. The most significant global impact is the Chinese Golden Week holiday that starts on October *. Numerous Chinese exporters and manufacturers slow down or shut...
Leave a Comment
Comments (0)